Benign Prostatic Hyperplasia, or BPH, is a condition in which the prostate enlarges as men age. BPH is very common, affecting nearly 500 million men worldwide. More than 40% of men in their 50s and more than 70% of men in their 60s have BPH.1 While BPH is a benign condition and unrelated to prostate cancer, it can greatly affect a man's quality of life.
A wide variety of treatments are available for men with BPH, including medication, minimally invasive therapies, and surgery. You and your doctor will consider several factors when you evaluate these choices.
The International Prostate Symptom Score (IPSS) is a common method for screening and diagnosing benign prostatic hyperplasia (BPH). The survey asks seven urinary symptom questions and one quality of life question to help determine the severity of your BPH.
Get answers to more than 20 frequently asked questions about The UroLift System.
The International Prostate Symptom Score (IPSS) is a method used to screen for and diagnose benign prostatic hyperplasia (BPH). The survey asks seven urinary symptom questions and one quality of life question to help determine the severity of your BPH.
Source Information
INFORMATION FOR PATIENTS ABOUT THE UROLIFT® SYSTEM
The UroLift System’s implants, which can be delivered during an outpatient procedure, relieve prostate obstruction without heating, cutting, destruction of, or removing prostate tissue.
The UroLift System can be used to treat a broad spectrum of anatomies, including obstructive median lobe.1 It is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction.*2-4
Most common side effects are temporary and can include pain or burning with urination, blood in the urine, pelvic pain, urgent need to urinate and/or the inability to control the urge.5 Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention.
Treatment using the UroLift System is not appropriate if you have a prostate volume greater than 100cc, a urinary tract infection or other conditions that can be identified by your urologist.
Individual results with the UroLift System may vary.
WARNINGS:
1) THE UROLIFT SYSTEM’S IMPLANTS ARE PERMANENT (THAT IS TO SAY: ONCE IMPLANTED, THEY CANNOT BE COMPLETELY REMOVED).
2) THE UROLIFT SYSTEM’S IMPLANTS CONTAIN STAINLESS STEEL AND NITINOL, AN ALLOY OF NICKEL AND TITANIUM. INDIVIDUALS WHO ARE ALLERGIC TO THESE METALS MAY SUFFER AN ALLERGIC REACTION TO THE IMPLANT. PRIOR TO HAVING A UROLIFT SYSTEM PROCEDURE, YOU SHOULD DISCUSS ANY ALLERGY/HYPERSENSITIVITY TO THESE MATERIALS WITH YOUR UROLOGIST.
3) THE ABOVEMENTIONED INFORMATION IS NOT INTENDED TO PROVIDE MEDICAL ADVICE TO PATIENTS OR TO REPLACE THEIR DOCTORS' EXPERT OPINION AND CARE.
4) ONLY A DOCTOR CAN DIAGNOSE WHETHER HIS/HER PATIENT HAS BPH, ASSESS HIS INDIVIDUAL CONDITION AND DEFINE WHETHER UROLIFT SYSTEM IS THE ADEQUATE TREATMENT OR NOT.
5) TALK TO YOUR UROLOGIST FOR MORE INFORMATION ABOUT THE UROLIFT SYSTEM AND TO DETERMINE IF IT IS THE RIGHT TREATMENT FOR YOU.
*No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study.
Teleflex, BPH Relief In Sight and UroLift are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. ©2023 Teleflex Incorporated. All rights reserved. Revised: 02/2023. MC-008657 LA EN
Teleflex Medical Brasil Ltda
Rua Alexandre Dumas, 2100/132 - Chacara Santo Antonio
São Paulo/SP - CEP 04717-913
